Arcutis Biotherapeutics stock
ARQTNASDAQArcutis Biotherapeutics, Inc., HealthcareISIN US03969K1088
62Score 62 out of 100, Neutral
Price and trend
75 / 100
Price history
+17% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 8.5% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 19% below its 52-week high. Largest decline in 7 years: 95% (February 2021 to November 2023).
Chart figures for advanced users
- SMA 50$27.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.37
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.50
- The lowest closing price of the last twelve months.
- Resistance$34.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arcutis Biotherapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.48B, is number 94 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $376.07M (up 91.3% year on year) and a loss of $16.14M.
- For fiscal 2026, analysts expect on average revenue of $538.56M (up 43.2%) and adjusted earnings per share of $0.48.
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 244 of 714 in Healthcare, median 53.
- Our model puts fair value at $33.43, with the price 15% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 71.9% a year through 2028 (estimates from 6 analysts).Growth 50
- Earnings turn into cashFree cash flow 200% of earnings over the last 12 months.Fundamentals 60
- More cash than debtCash $259.46M, financial debt $114.62M.Stability 53
Weaknesses
- DilutionShare count up 257% since 2020.Capital allocation 54
- Volatile share priceVolatility 56% a year over the last 12 months.Stability 53
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 61 to 62.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $23.88 and expensive above $55.71 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $62.20 (cash-flow model) and $4.65 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $28.36, at 8.4% it would be $40.76.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 60% on the twelve months before. Revenue turned from negative at the start of the period to positive ($376.07M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 90%, operating −3%, net −4%. Last 12 months: net 6%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.06 (expected $0.18)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.48−2.3%
- Revenue
- $538.56M+0.2%
- Earnings per share
- $1.31−0.9%
- Revenue
- $695.69M+1.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.5%2026 sales guidance raised to $525 million to $540 million from $480 million to $495 million.
“Based on the strength of our ZORYVE business to date, and in light of the incremental investments we are making to sustain demand for ZORYVE, we are delighted to raise our full-year 2026 sales guidance from the previous range of $480 million to $495 million to a range of $525 million to $540 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $3.97M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Matsuda MasaruSale
4 Nov 2026, EVP, Chief Legal Officer
- Shares
- 40,000
- Price
- $34.32
- Value
- $1.37M
- Matsuda MasaruSale
2 Nov 2026, EVP, Chief Legal Officer
- Shares
- 1,219
- Price
- $31.86
- Value
- $38,841
- Burnett PatrickSale
2 Nov 2026, EVP, Chief Medical Officer
- Shares
- 943
- Price
- $31.86
- Value
- $30,047
Show 18 more
- Watanabe ToddSale
2 Nov 2026, See Remarks
- Shares
- 4,377
- Price
- $31.86
- Value
- $139,466
- Welgus Howard G.Sale
15 Oct 2026, Board
- Shares
- 4,728
- Price
- $26.93
- Value
- $127,325
- Matsuda MasaruSale
16 Sept 2026, See Remarks
- Shares
- 3,674
- Price
- $25.00
- Value
- $91,853
- Welgus Howard G.Sale
15 Sept 2026, Board
- Shares
- 4,730
- Price
- $24.18
- Value
- $114,371
- Matsuda MasaruSale
8 Sept 2026, See Remarks
- Shares
- 9,989
- Price
- $25.03
- Value
- $249,986
- Curran TerrieSale
27 Aug 2026, Board
- Shares
- 27,052
- Price
- $25.03
- Value
- $677,095
- Curran TerrieSale
20 Aug 2026, Board
- Shares
- 1,072
- Price
- $26.04
- Value
- $27,912
- Burnett PatrickSale
19 Aug 2026, See Remarks
- Shares
- 1,697
- Price
- $27.00
- Value
- $45,819
- Welgus Howard G.Sale
17 Aug 2026, Board
- Shares
- 4,730
- Price
- $26.18
- Value
- $123,835
- Burnett PatrickSale
12 Aug 2026, See Remarks
- Shares
- 6,700
- Price
- $26.08
- Value
- $174,767
- Burnett PatrickSale
11 Aug 2026, See Remarks
- Shares
- 8,300
- Price
- $26.52
- Value
- $220,129
- Burnett PatrickSale
3 Aug 2026, See Remarks
- Shares
- 955
- Price
- $26.12
- Value
- $24,942
- Matsuda MasaruSale
3 Aug 2026, See Remarks
- Shares
- 1,230
- Price
- $26.12
- Value
- $32,124
- Watanabe ToddSale
3 Aug 2026, See Remarks
- Shares
- 4,375
- Price
- $26.12
- Value
- $114,261
- Welgus Howard G.Sale
15 Jul 2026, Board
- Shares
- 4,730
- Price
- $26.91
- Value
- $127,284
- Welgus Howard G.Sale
17 Jun 2026, Board
- Shares
- 635
- Price
- $25.67
- Value
- $16,300
- Lin Sue-JeanSale
15 Jun 2026, Board
- Shares
- 4,946
- Price
- $24.38
- Value
- $120,587
- Welgus Howard G.Sale
15 Jun 2026, Board
- Shares
- 4,096
- Price
- $24.41
- Value
- $99,980
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Arcutis Biotherapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Iovance BiotherapeuticsIOVA $3.74B43
- Denali TherapeuticsDNLI $3.72B37
- Viking TherapeuticsVKTX $3.63B34
- Legend BiotechLEGN $3.61B37
- Viridian TherapeuticsVRDN $3.55B47
- CelcuityCELC $3.55B28
- Dyne TherapeuticsDYN $3.37B36
- Disc MedicineIRON $3.34B42
ETFs that hold Arcutis Biotherapeutics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.22% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.22% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.18% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.11% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.04% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.